The past several years have seen major progress in the delivery of treatment and care to HIV-infected people in the developing world. However, substantial uncertainty persists regarding optimal treatment strategies, the cost of second- and third-line antiretroviral treatment, and the impact of expanded care. As the HIV epidemic continues to grow, these problems require critical analysis. In 2004, NIAID awarded our research group funding to develop the "Cost-effectiveness of Preventing AlDS Complications (CEPAC) International" Model, a computer simulation of the natural history, clinical management, outcomes, and costs of HIV disease in South Africa, Cote d'lvoire, and India. The current project has produced 16 publications, including a widely cited New England Journal of Medicine article, and another 9 submitted or draft manuscripts in its first 3 years. In this competing continuation, we request support to develop a 2nd generation CEPAC-International Model. This new model will reflect the most current understanding of HIV and AlDS epidemiology, treatment efficacy, impact on TB transmission and cost-effectiveness of care. The three specific aims of the current proposal are: 1) To refine the CEPAC-International Model's portrayal of critical patient- and population-level effects. This will include multiple entry cohorts staggered in time, person-to-person HIV transmission and TB transmission, long-term ART-related toxicities and co-morbidities, and to refine the approach to antiretroviral drug resistance. 2) To project clinical outcomes, cost, and cost-effectiveness of different patient-level treatment strategies for HIV care in developing countries;and 3) To identify optimal population-level HIV and AIDS treatment and prevention strategies in developing countries. The assembled research team has an extensive record of publishing and disseminating findings that inform priority setting in HIV care and practice guideline development, in the US and internationally. To augment the team's modeling capacity, skilled investigators with experience in HIV/TB co-infection, transmission dynamics as well as infectious disease modeling have been added to the team. By continuing the major progress already made by this multidisciplinary team, and accomplishing the specific aims described above, the proposed studies will address the most crucial HIV clinical policy and cost-effectiveness questions that will face providers and policy-makers in developing countries over the next several years.

Public Health Relevance

Despite recent progress globally to deliver HIV treatment and care to developing countries, major challenges remain in fully implementing these programs and understanding the clinical outcomes and cost-effectiveness of different strategies for HIV care worldwide. The CEPAC-International Model provides an inexpensive yet broadly applicable way of studying HIV interventions, projecting their outcomes, and highlighting important areas for future research. The flexibility of our program allows our team to investigate problems from several angles, providing insight into scenarios that may not be feasible to test in real-life settings through large-scale clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI058736-09
Application #
8289447
Study Section
Special Emphasis Panel (ZRG1-AARR-G (03))
Program Officer
Huebner, Robin E
Project Start
2003-09-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2012
Total Cost
$1,331,363
Indirect Cost
$307,175
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Ramirez-Avila, Lynn; Regan, Susan; Chetty, Senica et al. (2015) HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: Time trends over four years. Int J STD AIDS 26:704-9
Luz, Paula M; Morris, Bethany L; Grinsztejn, Beatriz et al. (2015) Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr 68:152-61
Doherty, Kathleen; Essajee, Shaffiq; Penazzato, Martina et al. (2014) Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res 14:201
Kaplan, Richard; Caldwell, Judy; Middelkoop, Keren et al. (2014) Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011). J Acquir Immune Defic Syndr 66:487-94
Tsai, Alexander C; Fricchione, Gregory L; Walensky, Rochelle P et al. (2014) Global health training in US graduate psychiatric education. Acad Psychiatry 38:426-32
Cardoso, Sandra W; Luz, Paula M; Velasque, Luciane et al. (2014) Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. AIDS Res Ther 11:29
Andrews, Jason R; Morrow, Carl; Walensky, Rochelle P et al. (2014) Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township. J Infect Dis 210:597-603
Bassett, Ingrid V; Govindasamy, Darshini; Erlwanger, Alison S et al. (2014) Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One 9:e85197
Drain, Paul K; Losina, Elena; Coleman, Sharon M et al. (2014) Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC Infect Dis 14:110
O?Laughlin, Kelli N; Kasozi, Julius; Walensky, Rochelle P et al. (2014) Clinic-based routine voluntary HIV testing in a refugee settlement in Uganda. J Acquir Immune Defic Syndr 67:409-13

Showing the most recent 10 out of 117 publications